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Summary In haemagglutination tests we have found that the monoclonal antibody B5 discriminates between
erythrocytes from patients with malignant cancer (total 386; >80% B5 positive) and individuals with no
known tumour (total 247; <20% B5 positive). The B5 antigen detected on intact erythrocytes is a tightly
bound surface component which does not appear to be derived from the plasma. The B5 antigen is not T, Tn,
Cal, CEA or the Forsmann antigen; nor is it related to any of the major blood group antigens. Abnormal
levels of surface B5 are found on erythrocytes from patients with a great diversity of tumours and this fact
presents B5 as an indirect marker of malignancy. Successful eradication of tumour is associated with a switch
from positive to negative B5 haemagglutination. We believe that B5 is a valuable addition to the few useful
tumour markers already employed for monitoring tumour status.
In a hydridoma fusion aimed at preparing
monoclonal antibody against the tumour-associated
Thomsen-Friedenreich (T) antigen (Springer et al.,
1975) we have obtained a product, designated B5,
with the unexpected property of agglutinating
erythrocytes from patients with malignant disease.
The Thomsen-Friedenreich (T) antigen is a
component of the human erythrocyte membrane
which is normally occluded by sialic acid
(Friedenreich, 1930). Initially B5 appeared to be
anti-T since it agglutinated desialylated, but not
intact erythrocytes and was neutralised by purified
glycophorin (T-antigenic glycoprotein kindly
donated by G.F. Springer). It was only a later,
definitive analysis which showed that B5 was not
anti-T since it did not react with the T-determinant
(Springer et al., 1975 and Springer, personal
communication). In the meantime, attempts to stain
leukaemic cells for T-antigen using B5 had, not
surprisingly, failed. However, when B5 was added
to the erythrocytes from these leukaemic patients
there was strong haemagglutination: this result was
unexpected since we knew that B5 did not
agglutinate erythrocytes from a normal donor.
Preliminary testing revealed that cancer patients in
general are positive for B5 haemagglutination
(Milner & Metcalfe, 1982) and the possibility arose
that B5 might be detecting a previously unknown,
and indirect, marker of malignant disease. Here we
have made a detailed clinical survey on the
incidence of B5 haemagglutination, and have
investigated some possible sources of B5 antigen.
Materials and methods
The B5 monoclonal antibody is a product of a
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fusion between Y3-Agl.2.3. rat myeloma cells
(Galfre et al., 1979) and spleen cells from an AO
rat immunised with desialylated human erythrocytes
(blood group 0). Each immunising dose was of 109
cells, the priming dose being in complete Freund's
adjuvant and intramuscular (i.m.). The first i.m.
boost was in incomplete Freund's and the second
i.m. boost was without adjuvant, each being at 4
week intervals. Three days after a final i.v. boost,
spleen cells were collected and fused with the Y3
cells using polyethylene glycol (B.D.H., mol.wt
1500) by standard procedure. Those supernatants
which caused agglutination of desialylated, but not
whole, erythrocytes were regarded as positive. In
the fusion from which B5 was obtained, B5 was the
only positive clone: in subsequent fusions a large
number of positive supernatants have been found,
though none have the binding properties of B5 (see
results). In this study we have used a pool of
supernatant with a titre of 1/128 against
desialylated erythrocytes. An equivalent titre was
maintained after storage of cloned cells in liquid
nitrogen.
Haemagglutination tests require a small volume
of heparinised blood: in this study 5ml was taken,
although 1ml would be ample. Appropriate
conditions for storage were assessed by testing
aliquots from samples kept at 4°C. Storage for up
to 7 days in these conditions did not alter the B5-
haemagglutination properties compared to the fresh
sample. For assay, 1 ml of whole blood was washed
3 times in 20ml PBS, pH 7.4, at room temperature.
A small volume of washed, packed erythrocytes was
then diluted to 1% in PBS containing 4% foetal
calf serum (FCS) and 25pl of this suspension was
added to 25,ul B5 antibody in a "U" well
haemagglutination plate. In controls 1%
erythrocytes were added to PBS containing 4%
FCS. or to culture supernatant containing an
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irrelevant antibody. The plates were covered with
film and left for at least 2h at room temperature
before being read. Haemagglutination was scored
positive or negative using an inverted microscope to
view the pellets directly under low power. Each
sample was also scored by direct examination of
cells gently resuspended and transferred onto a
glass slide. In the latter method clusters of less than
ten cells and representing <20% of the total were
regarded as negative; the rest scored positive.
Trypsin treatment was with 0.125% trypsin in
Ca+ +Mg+ +-free PBS at room temperature.
Neuraminidase was used at 1 i.u. ml-1 in 0.85%
NaCl containing 10-3M CaCl2 and incubated at
37°C for 2h unless otherwise stated: this treatment
causes extensive desialylation of the membrane
surface.
Results
Clinical
In the clinical survey we found that the B5
haemagglutination test discriminates between
erythrocytes from patients with malignant disease
and erythrocytes from individuals with no known
malignancy. The results given in Tables I and II
show that >80% of patients (total 386) with
various types of cancer were B5 positive. These
include each of 6 patients with tumours affecting
the central nervous system, a tumour type rarely
detected by other markers. Since the incidence of
B5 positivity was 80% in tumour patients and
-20% in each of the control groups, we conclude
that erythrocyte surface B5 antigen is markedly
increased in individuals who develop malignant
tumour. So far we have insufficient data to know if
B5 also discriminates between malignant and
benign tumours, though preliminary results
comparing women with benign and malignant
breast disease showed a lower incidence of B5
positively in pre-operative samples from the benign
group (4/8) in contrast to those with malignant
disease (12/13).
It is important to know whether successful
treatment of malignancy is associated with a switch
from B5 positive to B5 negative. For this purpose
data is now being accumulated in serial studies on
individual patients, and preliminary results indicate
that B5 haemagglutination decreases with time
during treatment when no active disease is
detectable (Table III). In addition, 14/15 patients
who had completed treatment for malignancy were
B5 negative (Table III). We anticipate that, where
B5 positivity reflects tumour presence, a switch in
B5 status to negative will occur several weeks after
tumour removal, due to the erythrocyte lifespan of
- 120 days. We have seen no clear correlation
between tumour load and B5 haemagglutination
titre (Metcalfe & Jamieson in preparation). It
follows that patients with an unstable tumour
which may show transient regression are unlikely to
become B5 negative.
Experimental
The B5 antibody was produced by immunising rats
with desialylated human erythrocytes. Using the
same immunisation protocol we have now prepared
over a hundred rat monoclonals, including anti-T
and anti-Tn (Metcalfe et al., In Press), but none of
these shares with B5 the property of selective
binding to erythrocytes from tumour patients. It
was not clear why B5 positively was strongly
associated with the presence of malignancy, nor
why some false positives occur in normal
individuals. The possibility arose that there was a
difference in the source of B5 antigen detected in
these two groups, and thus it was of interest to
determine whether the antigen is acquired, or
exposed through abnormal desialylation of the cell
surface. We have attempted to discriminate between
these two possibilities in experiments summarised in
Table IV. First, we found that brief trypsinisation
of intact B5-positive cells from normal or tumour
patients completely abolished B5-
haemagglutination: as expected B5-negative cells
remained negative following trypsin treatment. The
trypsinised form of each cell preparation became
strongly B5-positive when desialylated, thus
showing that both B5 positive and B5 negative cells
have an occluded population of B5 antigen. A
second treatment with trypsin of these now
desialylated cells caused a reduction in B5
haemagglutination which was similar for each
preparation. These observations suggest that surface
B5 antigen on erythrocytes from both normal and
tumour patients is in addition to, rather than a part
of, the occluded antigen. Although sensitive to
trypsin, surface B5 seemed to be tightly associated
with the membrane in that it could not be removed
by 1 mM EDTA. Whilst we have not yet identified
the nature of the surface B5 antigen,
haemagglutination tests with the relevant
monoclonal antibodies and lectins have excluded
the following known antigens as candidates: T, Tn,
carcinoembryonic antigen (CEA), Cal and the
Forsmann antigen. Comparison of donor blood
group with B5-haemagglutination showed no
correlation of surface B5 antigen with any of the
major blood group antigens.
We next considered the possibility that surface
B5 antigen may be acquired from the plasma, first
by screening plasma for free B5 antigen, andNEW INDICATOR OF HUMAN MALIGNANCY 339
Table I Washed erythrocytes were tested for B5 haemagglutination as detailed in Materials and
Methods. For individuals, the haemagglutination results of samples taken at different times remained
constant (with the exception of those cited in the text). The overall incidence of positive B5
haemagglutination was 88%
Type of cancer
(malignant)
Breast
Bladder
Leukaemias:
acute lymphoblastic
acute myeloblastic
chronic myeloid
chronic granulocytic
acute promyelocytic
acute monocytic
acute stem cell
chronic lymphatic
Ovary
Non-Hodgkin's lymphoma
Hodgkin's Disease
Bronchus and lung
Teratoma
Prostate
Stomach
Sarcoma
Ewing's sarcoma
Rhabdosarcoma
Leiomyosarcoma
Rectum
Cervix
Colon
Thyroid
Wilm's (kidney)
Uterus
Polycythaemia
Pancytopaenia
Pituitary
Seminoma
Larynx
Astrocytoma
Glioma
Pineal
Skin
Melanoma
Parotid
Oesophagus
Pancreas
Disgerminoma
Phaeochromocytoma
Secondary metastases:
bone
lymph nodes
Totals
No. ofindividuals
tested (total number
ofsamples given in
brackets)
87 (98)
84 (85)
26 (166)
10 (20)
3 (5)
1 (1)
1 (1)
1 (1)
1 (5)
1 (1)
29 (37)
21 (31)
16 (20)
17 (21)
10 (10)
7 (7)
6 (10)
1 (1)
2 (5)
2 (4)
2 (2)
5 (5)
5 (10)
4 (5)
4 (4)
3 (3)
3 (3)
3 (3)
3 (3)
3 (3)
3 (3)
2 (2)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
1 (1)
9 (12)
1 (1)
386 (598)
No. ofindividuals
showing haemagglutination
with B5
74/87
70/84
26/26
9/10
3/3
1
1
1
28/29
15/21
14/16
17/17
10/10
7/7
4/6
1
2/2
1/2
1/2
5/5
4/5
3/4
3/4
3/3
3/3
3/3
3/3
3/3
3/3
1/2
1
1
1
9/9
341 (88%)Table H B5 haemagglutination results from cancer patients and others
Haemagglutination with B5
No.
Individuals +ve -ve
Cancer patients (on treatment) 386 341 (88%) 45 (12%)
Controls:
Blood donors' 108 17 (16%) 91 (84%)
Renal patient on haemodialysis 44 8 (18%) 36 (82%)
Pregnant womenb 40 7 (18%) 33 (82%)
Others: 57 14 (25%) 43 (75%)
including colitis, pancreatitis, coeliac disease,
splenomegaly, diabetes mellitus, sickle cell
anaemia, hereditary spherocytosis, Down's
syndrome, arthritis, ankylosing spondylitis.
'N.B. There was no correlation with age nor with blood groups A, B, 0 or Rhesus.
bN.B. There was no correlation with gestational stage.
Table M B5 states of radiotherapy patients (a) serially recorded over a period of 6 months
and (b) of 15 patients off treatment
B5 status
(a) Radiotherapy patients
Constant Decreasing Increasing
(+)ve (-)ve (+)ve (+) ve
Group 1: No abnormality detected 1 2 8 0
Group 2: Active tumour: contained 0 0 0 1
few metastases 1 0 0 1
multiple metastases 1 0 0 3
Haemagglutination with B5
No. (+)ve (-)ve
(b) Cancerpatients (offtreatment
and apparently well) 15 1 14
Table IV
Eight different B5 positive tumour patients and several different controls have been tested, all giving results similar to
those presented here. Cells from the tumour patients and from non-cancer patients were subjected to trypsin and
neuraminidase treatment as indicated, and then retested for B5 agglutination (see Materials and methods for details)
Ist treatment 2nd treatment 3rd treatment Titre log2
Trypsin Neuraminidase Trypsin B5 haemag-
Erythrocyte source (min) (h) (min) glutination
Control 0
(B5 negative) 5 0
5 1 - 8
5 1 5 6
5 1 30 6
Control 3
(B5 positive) 5 - 0
5 1 8
5 1 5 6
Tumour patient - 3
(B5 positive) 5 0
5 1 8
5 1 5 6
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secondly by testing in vitro for any effects of plasma
on the B5 status of erythrocytes. In the first series
of experiments, the haemagglutination titre of B5
antibody stock was measured after preincubation
with plasma from either 9 tumour patients known
to be strongly B5 positive (Table Va), or with a set
of 8 serial samples obtained from a patient who
had changed from being strongly B5 positive to B5
negative (Table Vb). Neither series of plasma
significantly affected the B5 haemagglutination
titre, implying that free B5 antigen is not a plasma
component.
In a second series of experiments we looked for
changes in erythrocytes caused by incubation in
different plasmas or sera (Table VI). Incubation in
vitro with tumour-bearer plasma or serum had no
detectable effect on erythrocytes from normal
individuals, the cells remaining B5 negative.
Conversely, normal plasma or serum did not cause
B5 positive cells to become B5 negative. Thus we
have no evidence that surface B5 antigen in tumour
patients is acquired from plasma or serum, nor can
we show a role for plasma or serum in the
maintenance of B5 negativity in normal individuals.
Discussion
These results suggest that B5 detects a previously
unknown, indirect marker of malignant tumours.
We have no reason to suspect that B5-
haemagglutination is caused by therapy since the
incidence of B5 positive samples was the same in
untreated patients, as in those already on
Table V In (a), plasma (l00p1l) from 9 different patients
who were strongly B5 positive was mixed with 100p1 B5
on ice for 1 h. Each plasma-B5 mixture was then titrated
out to 10 doubling dilutions and assayed against the same
stock of B5-positive erythrocytes. Controls are indicated.
In (b), serial samples of plasma from a single leukaemic
patient who was B5 positive at early sample dates, and
became B5 negative after 5.X.82, were tested as in (a).
(a) Plasmafrom
patient No. B5 agglutination titre log2
1 6
2 6
3 7
4 6
5 6-7
6 6
7 6-7
8 6
9 6-7
Foetal calf serum 6
Human AB serum 6
Growth medium 5
(b) Patient "A" plasma:
Sample date Titre log2
28 IV 1982 4-5
12 V 1982 5
22 VI 1982 5
10 VIII 1982 6
5 X 1982 5
2 XI 1982 5-6
30 XI 1982 5-6
29 XII 1982 5-6
Table VI Serum from 6 patients with breast tumour were selected for a range of B5 status/tumour
type, including the only patient (1/13) who was B5 negative with malignant tumour and one with
benign tumour who was an exception in being strongly B5 positive. Erythrocytes from 3 different
donors were incubated at 37°C for 3h with each serum, washed twice in P.B.S., and then scored for B5
positively. The results using erythrocytes from patient No. 4 are given and are similar to those from
the two other donors. The score in parenthesis shows agglutination in the absence of B5 due to cross-
reacting antibodies in some donor sera (No. 1; No. 6). Similar results were obtained when plasma was
used in place of serum
Serumfrom Tumour B5 status Incubated B5 score
patient No. type ofpatient erythrocytes after incubation
I Benign - ++ (+)
2 Benign - + (-)
lBenign +++ From patient no. 4 +
4 Malignant +
5 Malignant - J + (-)
6 Malignant + + + + + (+ +)
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chemotherapy and/or radiotherapy. In serial studies
our finding that some tumour patients who had
been consistently B5 positive became B5 negative
towards the end of therapy, encourages us to
believe that such a switch from positive to negative
may indicate successful treatment of tumour. Since
the only requirement is a small blood sample, B5
provides a very simple, non-invasive test applicable
to a wide range of malignancies. We feel its greatest
worth will be in the monitoring of individuals for
tumour status, both for tumour regression during
therapy, and for tumour recurrence during follow-
up.
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